Combined targeting of Raf and Mek synergistically inhibits tumorigenesis in triple negative breast cancer model systems.

about

Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells.

P2860

Q55086907-845ED982-4735-4585-8C47-731DB028E75C

P2860

Combined targeting of Raf and Mek synergistically inhibits tumorigenesis in triple negative breast cancer model systems.

Item

http://www.wikidata.org/entity/Q47123785

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Combined targeting of Raf and ...... e breast cancer model systems.

@en

Combined targeting of Raf and ...... e breast cancer model systems.

@nl

type

Item

label

Combined targeting of Raf and ...... e breast cancer model systems.

@en

Combined targeting of Raf and ...... e breast cancer model systems.

@nl

prefLabel

Combined targeting of Raf and ...... e breast cancer model systems.

@en

Combined targeting of Raf and ...... e breast cancer model systems.

@nl

P1476

Combined targeting of Raf and ...... e breast cancer model systems.

@en

P2093

Changnian Shi

http://www.w3.org/2001/XMLSchema#string

Charles Leduc

http://www.w3.org/2001/XMLSchema#string

Peter A Greer

http://www.w3.org/2001/XMLSchema#string

Soma Sikdar

http://www.w3.org/2001/XMLSchema#string

Teddy S Nagaria

http://www.w3.org/2001/XMLSchema#string

Victoria Hoskin

http://www.w3.org/2001/XMLSchema#string

Waheed Sangrar

http://www.w3.org/2001/XMLSchema#string

P2860

Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas

Genes that mediate breast cancer metastasis to the brain

Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses

Triple negative breast cancer: looking for the missing link between biology and treatments

Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

P304

80804-80819

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.20534

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29113345

http://www.w3.org/2001/XMLSchema#string

P932

5655240

http://www.w3.org/2001/XMLSchema#string

Combined targeting of Raf and Mek synergistically inhibits tumorigenesis in triple negative breast cancer model systems.

about

P2860

P2860

Combined targeting of Raf and Mek synergistically inhibits tumorigenesis in triple negative breast cancer model systems.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932